Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $1.5 million.

  • Altimmune's Other Non-Current Assets fell 988.55% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 988.55%. This contributed to the annual value of $1.6 million for FY2024, which is 35151.52% up from last year.
  • Per Altimmune's latest filing, its Other Non-Current Assets stood at $1.5 million for Q3 2025, which was down 988.55% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Altimmune's Other Non-Current Assets registered a high of $1.7 million during Q2 2024, and its lowest value of $115300.0 during Q1 2021.
  • Moreover, its 5-year median value for Other Non-Current Assets was $811000.0 (2022), whereas its average is $919475.9.
  • Per our database at Business Quant, Altimmune's Other Non-Current Assets surged by 96875.85% in 2021 and then tumbled by 4523.81% in 2024.
  • Quarter analysis of 5 years shows Altimmune's Other Non-Current Assets stood at $872000.0 in 2021, then decreased by 29.47% to $615000.0 in 2022, then crashed by 40.98% to $363000.0 in 2023, then soared by 351.52% to $1.6 million in 2024, then dropped by 8.79% to $1.5 million in 2025.
  • Its Other Non-Current Assets stands at $1.5 million for Q3 2025, versus $1.6 million for Q2 2025 and $1.6 million for Q1 2025.